Stocks · News reference

TD Cowen Maintains Buy on Ascendis Pharma, Raises Price Target to $341

Aug 14, 2026, 4:00 PMBenzinga Newsdesk

TD Cowen analyst Yaron Werber maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $325 to $341.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 27, 2026, 2:52 PMAvi Kapoor
This Ascendis Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Analysts initiate coverage and change ratings on top stocks like ASND, DOCN, ODTX, MT, and NVCT. See their price targets and views on these stocks.
Read original at benzinga
ASND DOCN ODTX
BenzingaAug 27, 2026, 12:17 PMBenzinga Newsdesk
HC Wainwright & Co. Initiates Coverage On Ascendis Pharma with Buy Rating, Announces Price Target of $345
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rating and announces Price Target of $345.
Read original at benzinga
ASND
BenzingaAug 19, 2026, 10:07 AMBenzinga Newsdesk
BMO Capital Initiates Coverage On Ascendis Pharma with Outperform Rating, Announces Price Target of $319
BMO Capital analyst David Lebowitz initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Outperform rating and announces Price Target of $319.
Read original at benzinga
ASND
BenzingaAug 18, 2026, 12:03 PMBenzinga Newsdesk
Eyconis Announces First Patients Dosed In Phase 1b/2a OVERTURE Trial Of EYC-0305 In Treatment-Naïve Wet AMD Patients, Using TransCon Technology Licensed From Ascendis Pharma
Read original at benzinga
ASND